Phathom Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Phathom Pharmaceuticals
PHAT Stock  USD 17.53  1.16  7.09%   
Analyzing historical trends in various income statement and balance sheet accounts from Phathom Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Phathom Pharmaceuticals' valuation are summarized below:
Gross Profit
128.4 M
Profit Margin
(1.87)
Market Capitalization
1.2 B
Enterprise Value Revenue
8.1531
Revenue
147.2 M
There are currently one hundred twenty trending fundamental ratios for Phathom Pharmaceuticals that can be evaluated and compared over time across competitors. All traders should check out Phathom Pharmaceuticals' recent fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 665.2 M in 2026, whereas Enterprise Value is likely to drop slightly above 246.8 M in 2026.

Phathom Pharmaceuticals Total Revenue

66.72 Million

Check Phathom Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phathom Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 18.3 M, Depreciation And Amortization of 635.5 K or Interest Expense of 87 M, as well as many indicators such as Price To Sales Ratio of 10.14, Dividend Yield of 0.0 or Days Sales Outstanding of 280. Phathom financial statements analysis is a perfect complement when working with Phathom Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Phathom Stock
Check out the analysis of Phathom Pharmaceuticals Correlation against competitors.
For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.

Phathom Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets267.1 M435.1 M141.7 M
Slightly volatile
Short and Long Term Debt Total670.1 M638.2 M134.2 M
Slightly volatile
Other Current Liabilities66.3 M63.2 M15 M
Slightly volatile
Total Current Liabilities103.5 M98.6 M26.5 M
Slightly volatile
Accounts Payable8.8 M12.1 M4.5 M
Slightly volatile
Cash243.5 M341.9 M126 M
Slightly volatile
Cash And Short Term Investments243.5 M341.9 M126 M
Slightly volatile
Common Stock Shares Outstanding40.4 M72.7 M25.8 M
Slightly volatile
Liabilities And Stockholders Equity267.1 M435.1 M141.7 M
Slightly volatile
Capital Surpluse458.1 M691.8 M271.8 M
Slightly volatile
Other Current Assets25.2 M24 M6.3 M
Slightly volatile
Other Stockholder Equity657.4 M1.2 B353 M
Slightly volatile
Total Liabilities763 M726.7 M183.2 M
Slightly volatile
Short and Long Term Debt5.1 M8.5 M4.4 M
Slightly volatile
Total Current Assets259.7 M414.2 M137.3 M
Slightly volatile
Short Term Debt24.5 M23.3 M5.6 M
Slightly volatile
Other Liabilities5.8 M8.6 M4.1 M
Slightly volatile
Property Plant And Equipment Net3 M2.4 M2 M
Slightly volatile
Other Assets816.6 K723.6 K521.2 K
Slightly volatile
Long Term Debt243.2 M231.6 M74.5 M
Slightly volatile
Common Stock Total Equity2.9 K3.5 K2.4 K
Slightly volatile
Long Term Debt Total55.8 M103.1 M46.2 M
Slightly volatile
Capital Lease Obligations428.4 K450.9 K943.3 K
Pretty Stable
Property Plant And Equipment Gross4.2 M5.7 M2.7 M
Slightly volatile
Non Current Liabilities Other416.3 M396.5 M95.1 M
Slightly volatile
Common Stock4 K6.9 K3 K
Slightly volatile
Property Plant Equipment2.4 M4 M2.1 M
Slightly volatile

Phathom Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization635.5 K914.2 K905.5 K
Slightly volatile
Interest Expense87 M82.8 M19.2 M
Slightly volatile
Selling General Administrative351 M334.3 M76.6 M
Slightly volatile
Other Operating Expenses401.8 M382.6 M108 M
Slightly volatile
Research Development48.6 M30.7 M29.7 M
Slightly volatile
Total Operating Expenses392.1 M373.5 M106.3 M
Slightly volatile
Cost Of Revenue9.6 M9.2 M1.7 M
Slightly volatile
Reconciled Depreciation521 K914.2 K255.8 K
Slightly volatile

Phathom Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.7 M1.7 M12 M
Very volatile
Net Borrowings59.2 M68.3 M30.6 M
Slightly volatile
Other Cashflows From Financing Activities1.4 M1.4 M32.6 M
Pretty Stable
Depreciation960 K914.2 K281.7 K
Slightly volatile
Other Non Cash Items42.3 M52.2 M27.3 M
Slightly volatile
Capital Expenditures115.4 K121.5 K1.8 M
Very volatile
Total Cash From Financing Activities178.5 M210.2 M90.6 M
Slightly volatile
End Period Cash Flow244.4 M345.1 M126.6 M
Slightly volatile
Change To Netincome47.3 M38.7 M27.5 M
Slightly volatile
Stock Based Compensation21.3 M27.7 M9.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.1410.68567
Slightly volatile
Days Sales Outstanding280295770
Slightly volatile
Stock Based Compensation To Revenue0.480.554.4519
Slightly volatile
Capex To Depreciation0.190.21.9 K
Slightly volatile
EV To Sales15.2416.04275
Slightly volatile
Payables Turnover0.720.680.1452
Slightly volatile
Research And Ddevelopement To Revenue0.670.7160.3716
Slightly volatile
Capex To Revenue0.00270.00281.9736
Slightly volatile
Cash Per Share4.544.232.8981
Slightly volatile
Days Payables Outstanding52655322.2 K
Slightly volatile
Income Quality0.540.720.7262
Pretty Stable
Current Ratio4.594.836.8823
Pretty Stable
Receivables Turnover0.741.280.5457
Slightly volatile
Capex Per Share0.00230.00250.6069
Slightly volatile
Revenue Per Share0.830.790.1577
Slightly volatile
Interest Debt Per Share9.388.932.4935
Slightly volatile
Debt To Assets1.771.691.5323
Slightly volatile
Days Of Payables Outstanding52655322.2 K
Slightly volatile
Ebt Per Ebit1.431.391.1961
Slightly volatile
Long Term Debt To Capitalization1.261.710.7812
Slightly volatile
Total Debt To Capitalization1.381.662.2721
Slightly volatile
Quick Ratio4.554.796.8737
Pretty Stable
Net Income Per E B T0.81.020.911
Slightly volatile
Cash Ratio3.793.996.5013
Pretty Stable
Days Of Sales Outstanding280295770
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.231.151.4313
Slightly volatile
Fixed Asset Turnover24.9923.84.5809
Slightly volatile
Debt Ratio1.771.691.5323
Slightly volatile
Price Sales Ratio10.1410.68567
Slightly volatile
Asset Turnover0.140.130.0258
Slightly volatile
Gross Profit Margin0.650.770.7557
Very volatile

Phathom Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap665.2 M589.9 M422.1 M
Slightly volatile
Enterprise Value246.8 M259.8 M311.7 M
Slightly volatile

Phathom Fundamental Market Drivers

Phathom Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Phathom Pharmaceuticals Financial Statements

Phathom Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Phathom Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Phathom Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Phathom Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue21.1 M22.1 M
Total Revenue63.5 M66.7 M
Cost Of Revenue9.2 M9.6 M
Stock Based Compensation To Revenue 0.50  0.48 
Research And Ddevelopement To Revenue 0.71  0.67 
Revenue Per Share 0.79  0.83 
Ebit Per Revenue(4.52)(4.75)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY